## Diagnosis: Invasive Pulmonary Aspergillosis (IPA) ### Clinical & Radiologic Hallmarks **Key Point:** The **halo sign** (ground-glass opacity surrounding a nodule) is the pathognomonic early radiologic finding of invasive pulmonary aspergillosis in neutropenic patients. It represents hemorrhage around the nodule due to angioinvasion. **High-Yield:** Serum galactomannan antigen positivity is a sensitive and specific biomarker for *Aspergillus fumigatus* infection. This test has ~90% sensitivity in IPA and is widely used for diagnosis and monitoring. ### Halo Sign: Pathophysiology 1. *Aspergillus* hyphae invade pulmonary blood vessels 2. Vessel wall damage → hemorrhage into surrounding lung parenchyma 3. CT appearance: nodule surrounded by ground-glass opacity (hemorrhage) 4. Typically appears in the first 2 weeks of infection **Clinical Pearl:** The halo sign is most common in severely immunocompromised patients (AML on chemotherapy, CD4 <50 cells/μL in HIV). As immune recovery occurs, the halo may resolve and cavitation may develop (air-crescent sign). ### Diagnostic Criteria for IPA | Criterion | Finding | |-----------|----------| | **Host factor** | Neutropenia (ANC <500 cells/μL), hematologic malignancy | | **Clinical features** | Fever, cough, hemoptysis, dyspnea unresponsive to antibiotics | | **Imaging** | Halo sign, air-crescent sign, nodules | | **Biomarkers** | Galactomannan antigen (serum or BAL), β-D-glucan | | **Histology** | Septate hyphae with acute-angle (45°) branching | ### Aspergillus vs. Mucormycosis: Key Differences | Feature | Aspergillosis | Mucormycosis | |---------|---------------|---------------| | **Risk factor** | Neutropenia, hematologic malignancy | Diabetes (DKA), organ transplant | | **Hyphal morphology** | Septate, acute-angle branching | Non-septate, right-angle branching | | **Angioinvasion** | Moderate | Marked | | **Halo sign** | Present (early) | Rare | | **Tissue necrosis** | Cavitation, hemorrhage | Black eschar | | **Galactomannan** | Positive | Negative | | **DOC** | Voriconazole | Amphotericin B liposomal | **Mnemonic: FUME** (Features of *Aspergillus fumigatus*) - **F**ilamentous fungus - **U**biquitous in environment (spores inhaled) - **M**ost common *Aspergillus* species in IPA - **E**arly halo sign in neutropenic patients ### Antifungal Management of IPA **High-Yield:** Voriconazole is the first-line agent for invasive aspergillosis, including IPA. ```mermaid flowchart TD A[Invasive Pulmonary Aspergillosis]:::outcome --> B{Renal function & Drug interactions?}:::decision B -->|Normal renal function, no CI| C[Voriconazole IV 6 mg/kg Q12H × 2 doses, then 4 mg/kg Q12H]:::action B -->|Renal impairment or CI| D[Liposomal amphotericin B 3-5 mg/kg/day]:::action C --> E[Therapeutic drug monitoring: trough 1-5.5 μg/mL]:::action D --> F[Switch to voriconazole or posaconazole when stable]:::action E --> G[Clinical & radiologic response at 2-4 weeks]:::outcome F --> G ``` **Dosing & Monitoring:** - **Voriconazole:** IV 6 mg/kg Q12H × 2 loading doses, then 4 mg/kg Q12H - **Therapeutic drug monitoring (TDM):** Trough level 1–5.5 μg/mL (critical for efficacy and toxicity) - **Duration:** Minimum 6–12 weeks, depending on clinical response and immune recovery **Warning:** Voriconazole has significant drug interactions (CYP3A4 inhibitor) and hepatotoxicity. Monitor LFTs and drug levels closely. ### Why Voriconazole Over Amphotericin B? - Superior CNS penetration (important if dissemination occurs) - Better clinical outcomes in comparative trials - Oral bioavailability allows step-down to oral therapy - Amphotericin B reserved for renal impairment or voriconazole intolerance [cite:Harrison 21e Ch 209; Robbins 10e Ch 8]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.